• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives Chlorinated biphenyls

Introduction to 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid (CAS No. 1261914-27-5)

4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid, identified by the chemical abstracts service number 1261914-27-5, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound, featuring a benzoic acid core with substituents at the 3- and 4-positions, exhibits a unique structural configuration that makes it a promising candidate for various biochemical applications. The presence of both a carboxylic acid group and a hydroxyl group, coupled with a chlorophenyl moiety, contributes to its diverse reactivity and potential biological activity.

The molecular structure of 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid can be described as a benzoic acid derivative with a chloro-substituted phenyl ring at the 3-position and a carboxy-substituted phenyl ring at the 4-position. This arrangement imparts specific electronic and steric properties to the molecule, which are critical for its interaction with biological targets. The compound's solubility profile, thermal stability, and metabolic pathways are also influenced by these structural features, making it an intriguing subject for further investigation.

In recent years, there has been growing interest in developing novel compounds that can modulate biological pathways associated with inflammation, cancer, and metabolic disorders. 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid has been studied for its potential role in these areas due to its structural similarity to known bioactive molecules. Researchers have explored its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), to assess its suitability for therapeutic applications.

One of the most compelling aspects of 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid is its ability to interact with various enzymes and receptors. Preliminary studies have suggested that this compound may inhibit certain enzymes involved in the inflammatory response, such as cyclooxygenase (COX) and lipoxygenase (LOX). Additionally, its structural features may allow it to bind to specific receptors that are implicated in cancer progression, making it a potential lead compound for developing targeted therapies.

The synthesis of 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid has been optimized through multiple synthetic routes to ensure high yield and purity. Advanced techniques such as catalytic hydrogenation, palladium-catalyzed cross-coupling reactions, and enzymatic modifications have been employed to achieve the desired product. These synthetic strategies not only enhance the efficiency of production but also allow for the introduction of additional functional groups if needed.

From a regulatory perspective, 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid must meet stringent quality control standards before it can be considered for clinical use. Analytical methods such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) are employed to verify its chemical identity and purity. These analytical techniques provide detailed information about the compound's molecular structure and ensure that it meets the required specifications.

The pharmacological activity of 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid has been evaluated in both in vitro and in vivo models. In cell culture experiments, this compound has demonstrated inhibitory effects on several key enzymes involved in inflammation and cancer metabolism. For instance, studies have shown that it can reduce the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Similarly, in animal models of cancer, 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid has exhibited promising anti-proliferative effects on tumor cells without significant toxicity to healthy tissues.

The development of new therapeutic agents often involves understanding their interaction with biological targets at the molecular level. Computational methods such as molecular docking and molecular dynamics simulations have been utilized to predict how 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid interacts with its intended targets. These simulations provide valuable insights into the binding affinity and specificity of the compound, helping researchers refine its structure for improved efficacy.

Another area of interest is the potential use of 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid in combination therapies. By pairing it with other bioactive molecules or drugs that target different pathways, researchers aim to achieve synergistic effects that could enhance therapeutic outcomes. Preclinical studies have explored combinations of this compound with traditional chemotherapeutic agents and immunomodulators, providing evidence of improved anti-cancer activity.

The future prospects for 4-(3-Carboxy-4-chlorophenyl)-3-hydroxybenzoic acid are promising, with ongoing research focused on optimizing its pharmacological properties and exploring new applications. As our understanding of disease mechanisms continues to evolve, this compound may find utility in treating a wide range of conditions beyond inflammation and cancer. Collaborative efforts between academic institutions, pharmaceutical companies, and regulatory agencies will be crucial in translating these findings into clinical practice.

• 1261938-18-4(2-Chloro-4-(2-hydroxyphenyl)benzoic acid)
• 1183275-86-6(2-chloro-5-(2,5-dimethoxyphenyl)benzoic Acid)
• 1261938-26-4(2-chloro-4-(3-hydroxyphenyl)benzoic Acid)
• 1195344-56-9(2-Chloro-5-hydroxy-4-methylbenzoic acid)
• 1261902-90-2(4-(3-Carboxy-4-chlorophenyl)-2-formylphenol)
• 1261925-56-7(2-Chloro-4-(2,5-dimethoxyphenyl)benzoic acid)
• 1261898-48-9(4-(2,5-Dichlorophenyl)-3-hydroxybenzoic acid)
• 1261902-01-5(4-(4-Chloro-3-methylphenyl)-3-hydroxybenzoic acid)
• 1261933-49-6(2-(3-Carboxy-4-chlorophenyl)phenol)
• 1018687-71-2(4-chloro-3-(2-hydroxyphenyl)benzoic acid)